158 related articles for article (PubMed ID: 36350065)
1. Diagnostic and Prognostic Value of Isolated and Combined MCM3 and Glypican-3 Expression in Hepatocellular Carcinoma: A Novel Immunosubtyping Prognostic Model.
Mohamed AS; Abd El Hafez A; Eltantawy A; Mahfouz M
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):694-702. PubMed ID: 36350065
[TBL] [Abstract][Full Text] [Related]
2. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
[TBL] [Abstract][Full Text] [Related]
3. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
4. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy.
Chen IP; Ariizumi S; Nakano M; Yamamoto M
J Gastroenterol; 2014 Jan; 49(1):117-25. PubMed ID: 23532638
[TBL] [Abstract][Full Text] [Related]
5. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.
Zhang J; Zhang M; Ma H; Song X; He L; Ye X; Li X
Medicine (Baltimore); 2018 Jun; 97(24):e11130. PubMed ID: 29901640
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.
Li J; Gao JZ; Du JL; Wei LX
World J Gastroenterol; 2014 May; 20(20):6336-44. PubMed ID: 24876756
[TBL] [Abstract][Full Text] [Related]
9. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma.
Karaoğullarindan Ü; Gümürdülü Y; Üsküdar O; Odabaş E; Güler HS; Tozluklu N; Bağir E; Kuran S
Eur J Gastroenterol Hepatol; 2023 Jan; 35(1):89-93. PubMed ID: 36165051
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.
Wang YL; Zhu ZJ; Teng DH; Yao Z; Gao W; Shen ZY
World J Gastroenterol; 2012 May; 18(19):2408-14. PubMed ID: 22654434
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients.
Ning S; Bin C; Na H; Peng S; Yi D; Xiang-hua Y; Fang-yin Z; Da-yong Z; Rong-cheng L
Mol Biol Rep; 2012 Jan; 39(1):351-7. PubMed ID: 21655958
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
15. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.
Haruyama Y; Yorita K; Yamaguchi T; Kitajima S; Amano J; Ohtomo T; Ohno A; Kondo K; Kataoka H
Int J Cancer; 2015 Oct; 137(7):1643-51. PubMed ID: 25784484
[TBL] [Abstract][Full Text] [Related]
16. [The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma].
Zhang PR; Ma XL; Guo L; Lu RQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jun; 57(6):885-890. PubMed ID: 37357208
[No Abstract] [Full Text] [Related]
17. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.
Xiao WK; Qi CY; Chen D; Li SQ; Fu SJ; Peng BG; Liang LJ
BMC Cancer; 2014 Feb; 14():104. PubMed ID: 24548704
[TBL] [Abstract][Full Text] [Related]
18. Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma.
Kawaida M; Yamazaki K; Tsujikawa H; Fukuma M; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Pathol Int; 2019 Mar; 69(3):125-134. PubMed ID: 30729617
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
